Form 4: Beta Bionics CPO Sells Shares for Tax Obligations

Beta Bionics' Chief Product Officer, Mike Mensinger, sold 1,089 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Mike Mensinger, Chief Product Officer of Beta Bionics, Inc. (BBNX), reported a transaction on September 2, 2025.
• The transaction involved the sale of 1,089 shares of common stock.
• The shares were sold at a weighted average price of $18.8632 per share.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following this transaction, Mr. Mensinger directly beneficially owns 91,815 shares of common stock.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive because the transaction stems from the vesting of restricted stock units, which is a positive compensation event for the officer. The subsequent sale is a routine tax-related action rather than a discretionary sale indicating a lack of confidence.

Positives

• The sale was a result of restricted stock units (RSUs) vesting, indicating a positive event for the officer in terms of compensation and retention.

Negatives

• The Chief Product Officer reduced his direct ownership by 1,089 shares, although this was for tax purposes.

Future Outlook

The filing does not contain any forward-looking statements or guidance.

Industry Context

This Form 4 filing is a routine disclosure of insider stock transactions, common across all industries when executive compensation involves equity awards that vest and require tax coverage.

Stakeholder Impact

• Shareholders: The sale of a relatively small number of shares for tax purposes by an insider is unlikely to have a significant impact on the company's stock price or investor sentiment.

Key Dates

Keywords

Beta Bionics, BBNX, Insider Trading, Form 4, Stock Sale, Restricted Stock Units, Tax Withholding, Chief Product Officer